News

A cautious market traded AstraZeneca stock down by more than 2% following the report, on a day when the S&P 500 index landed ...
AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ...
Shares in Summit Therapeutics have risen sharply on a report that AstraZeneca is in discussions for a partnership focused on ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
At ASCO Day 1, Summit Therapeutics crashes the party again, Pfizer's drug demonstrates "unprecedented" survival rate, and more. ... AstraZeneca’s plenary streak continues: ...